Cargando…
Atezolizumab-related encephalitis in the intensive care unit: Case report and review of the literature
Atezolizumab is a monoclonal antibody that targets programmed death ligand-1. Treatments with this drug may cause immune-related adverse events by creating an exaggerated inflammatory response. The most common side effects are fatigue, rash, and gastrointestinal symptoms. Cases of central nervous sy...
Autores principales: | Laserna, Andrés, Tummala, Sudhakar, Patel, Neel, El Hamouda, Diaa Eldin Mohamed, Gutiérrez, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088478/ https://www.ncbi.nlm.nih.gov/pubmed/30116528 http://dx.doi.org/10.1177/2050313X18792422 |
Ejemplares similares
-
Autoimmune Encephalitis in the Intensive Care Unit
por: Diaz-Arias, Luisa A., et al.
Publicado: (2019) -
Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review
por: Arakawa, Masafumi, et al.
Publicado: (2018) -
Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review
por: Özdirik, Burcin, et al.
Publicado: (2021) -
Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review
por: Satake, Tomoyuki, et al.
Publicado: (2022) -
Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2020)